Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

GlobeNewswire September 27, 2021

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy

GlobeNewswire September 23, 2021

Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference

GlobeNewswire September 22, 2021

Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 8, 2021

Daré Bioscience to Participate in Panel Discussion at Women's Health Innovation Summit

GlobeNewswire September 7, 2021

Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause

GlobeNewswire September 1, 2021

Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

GlobeNewswire August 12, 2021

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

GlobeNewswire August 9, 2021

Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021

GlobeNewswire August 5, 2021

Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021

GlobeNewswire July 26, 2021

Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive

GlobeNewswire July 12, 2021

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1

GlobeNewswire June 28, 2021

Daré Bioscience to Present at 2021 BIO Digital

GlobeNewswire June 4, 2021

Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update

GlobeNewswire May 13, 2021

Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021

GlobeNewswire May 6, 2021

Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

GlobeNewswire April 27, 2021

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

GlobeNewswire April 26, 2021

Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

GlobeNewswire April 19, 2021

Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update

GlobeNewswire March 30, 2021

Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

GlobeNewswire March 24, 2021